Results 41 to 50 of about 2,301 (144)

Diagnostic antibodies at an inflection point: From discovery platforms to design‐oriented engineering

VIEW, EarlyView.
This study systematically organizes the evolution of diagnostic antibodies from discovery platforms to design‐oriented engineering and analyzes the strengths and limitations of each approach. Meanwhile, it provides a critical, literature‐driven synthesis of current challenges, proposing integrated strategies for assay‐aware and function‐driven antibody
Qitao Song, Lulai Xu, Weilin Wu, Fei Xie, Yantong Pan, Tiantian Yang, Xiaoxia Xu, Yanyin Lin, Lihua Zhang, Jiahui Zhou, Junyou Zhou, Linping Li, Zhanhui Wang, Weijing Yi, Jing Wang   +14 more
wiley   +1 more source

Design and Characterization of Bispecific and Trispecific Antibodies Targeting SARS-CoV-2

Vaccines
Background/Objectives: COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic since its outbreak in 2019. As an increasing number of variants have emerged, especially concerning variants such as Omicron BA.1, BA.2, XBB.1, EG.5, which can escape
Jiayang Wang, Qi Qian, Yushan Jiang, Zuxin Liang, Yun Peng, Wei Zhao, Yang Yang, Chenguang Shen   +7 more
doaj   +1 more source

Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities

mAbs, 2022
Controlled Fab arm exchange (cFAE) has proven to be a generic and versatile technology for the efficient generation of IgG-like bispecific antibodies (DuoBodies or DBs), with several in clinical development and one product, amivantamab, approved by the ...
Desislava Yanakieva, Lukas Pekar, Andreas Evers, Markus Fleischer, Stephan Keller, Dirk Mueller-Pompalla, Lars Toleikis, Harald Kolmar, Stefan Zielonka, Simon Krah   +9 more
doaj   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Highly sensitive detection of antibody nonspecific interactions using flow cytometry

mAbs, 2021
The rapidly evolving nature of antibody drug development has resulted in technologies that generate vast numbers (hundreds to thousands) of lead antibody candidates during early discovery.
Emily K. Makowski, Lina Wu, Alec A. Desai, Peter M. Tessier   +3 more
doaj   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Discovery and characterization of single-domain antibodies for polymeric Ig receptor-mediated mucosal delivery of biologics

mAbs, 2020
Mucosal immunity is dominated by secretory IgA and IgM, although these are less favorable compared to IgG molecules for therapeutic development. Polymeric IgA and IgM are actively transported across the epithelial barrier via engagement of the polymeric ...
Bharathikumar Vellalore Maruthachalam, Adam Zwolak, Xiefan Lin-Schmidt, Edward Keough, Ninkka Tamot, Sathya Venkataramani, Brian Geist, Sanjaya Singh, Rajkumar Ganesan   +8 more
doaj   +1 more source

Affinity Enhancement in Discrete Multivalent MegaMolecules

ChemBioChem, Volume 27, Issue 11, 15 June 2026.
We design discrete protein megamolecules with precisely controlled valency (1–6 nanobodies), which exhibit strong avidity‐driven affinity enhancement toward epidermal growth factor receptor and human epidermal growth factor receptor. We systematically investigate the roles of valency, intrinsic affinity, and spatial presentation in optimizing binding ...
Zhaoyi Gu, Blaise R. Kimmel, Justin A. Modica, Che‐Fan Huang, Rahul K. Salaria, Sraeyes Sridhar, Neil L. Kelleher, Milan Mrksich   +7 more
wiley   +1 more source

Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies [PDF]

Cancer Biotherapy and Radiopharmaceuticals, 2010
Antibodies are highly versatile proteins with the ability to be used to target diverse compounds, such as radionuclides for imaging and therapy, or drugs and toxins for therapy, but also can be used unconjugated to elicit therapeutically beneficial responses, usually with minimal toxicity.
Robert M, Sharkey, Edmund A, Rossi, Chien-Hsing, Chang, David M, Goldenberg   +3 more
openaire   +2 more sources